More Good News For Glaxo22 Jan 2021 09:31
ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment
Cabenuva allows virologically suppressed adults living with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine to maintain viral suppression with 12 dosing days per year
London, 21 January 2021 - ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc ("GSK")